New hope for ALK lung cancer patients: targeted pill after radiation may delay progression
NCT ID NCT07235306
First seen Nov 19, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tests whether taking ensartinib (a targeted pill) after chemoradiation can help people with ALK-mutated stage III lung cancer that cannot be removed by surgery. About 45 adults who have finished chemoradiation without their cancer getting worse will be randomly assigned to receive either ensartinib or a placebo. The goal is to see if the drug delays cancer growth and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.